After a year of historic profits in 2021 following the mass roll-out of COVID-19 vaccines and related treatments, big pharma companies armed with cash for deals have been shifting their attention -
Overall, pharma, medical...more
2/3/2023
/ Acquisitions ,
Biotechnology ,
Coronavirus/COVID-19 ,
Global Dealmaking ,
Healthcare ,
Investment ,
Investors ,
Life Sciences ,
Mergers ,
Pharmaceutical Industry ,
Prescription Drugs ,
Vaccinations
Although the record-breaking deal activity of 2021 spilled over into 2022, headwinds in the first quarter developed into a significant slowdown during the rest of 2022, with an expectation of continued slowness as we enter...more
1/30/2023
/ Acquisitions ,
Buyers ,
Capital Markets ,
CFIUS ,
Coronavirus/COVID-19 ,
Cryptocurrency ,
Department of Justice (DOJ) ,
Domestic Dealmaking ,
Environmental Social & Governance (ESG) ,
EU ,
Federal Trade Commission (FTC) ,
Financial Institutions ,
Financial Services Industry ,
Global Dealmaking ,
Investment ,
Investors ,
Mergers ,
Pharmaceutical Industry ,
Private Equity ,
Publicly-Traded Companies ,
Real Estate Market ,
Securities and Exchange Commission (SEC) ,
Sellers ,
Special Purpose Acquisition Companies (SPACs) ,
Technology
While global dealmaking in Q1 was down from a blockbuster 2021, there are signs deal activity could pick up later in the year -
Following a record-breaking year for dealmaking, 2022 has had a relatively slow start. A total...more
4/8/2022
/ Acquisitions ,
Activision ,
Banking Sector ,
Canada ,
Coronavirus/COVID-19 ,
Gaming ,
Global Dealmaking ,
Global Market ,
Investment ,
Investors ,
Mergers ,
Real Estate Market ,
Software ,
Technology ,
Video Games
M&A markets appeared to defy gravity through 2021. Globally, dealmakers were highly active, with values exceeding US$5 trillion for the first time ever. Total deal value rose by 81 percent on 2020 totals to US$5.75 trillion,...more
Five factors that will shape dealmaking over the coming 12 months -
Last year will be a very tough act to follow. M&A values and volumes soared on the back of confident public markets, strong deal financing options and a...more
2/7/2022
/ Acquisitions ,
Coronavirus/COVID-19 ,
Domestic Dealmaking ,
Federal Trade Commission (FTC) ,
Interest Rates ,
Mergers ,
Private Equity ,
Regulatory Oversight ,
Securities and Exchange Commission (SEC) ,
Special Purpose Acquisition Companies (SPACs) ,
Stock Markets
Global dealmaking was consistently strong in 2021, with the value topping US$1 trillion in each quarter for the first time on record. This achievement is particularly impressive given the tumultuous deal environment, as M&A...more
Heightened interest in medical suppliers, contract research organizations and biotech firms resulted in an impressive year for healthcare dealmaking-
Dealmaking within the pharma, medical and biotech sector continued from...more
12/21/2021
/ Acquisitions ,
Biotechnology ,
Coronavirus/COVID-19 ,
Domestic Dealmaking ,
Healthcare ,
Investment ,
Investors ,
Life Sciences ,
Medical Research ,
Mergers ,
Special Purpose Acquisition Companies (SPACs) ,
Technology
Despite a drop on the previous quarter, Q3 2021 global M&A value represented the strongest Q3 on Mergermarket record -
The third quarter is usually a sleepy one for M&A—but not so this year. A total of US$1.4 trillion in...more
After a turbulent 18 months which saw M&A crash before an impressive return to form, H2 2021 is set for continued strong deal activity, as well as new challenges -
US M&A progressed steadily through the first half of 2021....more
8/10/2021
/ Acquisitions ,
Biden Administration ,
CFIUS ,
Coronavirus/COVID-19 ,
Domestic Dealmaking ,
Enforcement ,
Global Dealmaking ,
Investment ,
Liquidity ,
Mergers ,
National Security ,
Securities and Exchange Commission (SEC) ,
Special Purpose Acquisition Companies (SPACs) ,
Stock Markets ,
Technology Sector ,
Vaccinations
Healthy deal activity has returned to the leisure and retail sectors—areas of the economy that were among the worst affected by the pandemic.
Together, the leisure and retail sectors saw M&A value reach US$41.7 billion...more
A brightening macroeconomic outlook and supportive deal environment helped push second-quarter value to a new record
Dealmakers hoping for a 2021 rebound in M&A activity have not been disappointed. In Q2 2021, M&A value...more
A majority of dealmakers say their companies are focused on defense or survival, but about a quarter are actively pursuing growth.
According to Mergermarket, the value of US M&A in the second quarter of 2020 was lower...more